Metrics as of 10/13/2026, 06:52 PM (Berlin time), refresh in progress.
Pelthos Therapeutics Stock
Pelthos Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Scott Plesha
- Employees
- 92
- Market cap
- $77 M
- IPO
- 16/02/2024
- Web
- pelthos.com
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in…
Pelthos Therapeutics stock: price history
1D
+3.2%
1W
-6.2%
1M
-8.0%
6M
-12.4%
YTD
-35.0%
1Y
-13.0%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~27% weaker price swings than usual
Ask the agents about Pelthos Therapeutics
Analyst assessment of Pelthos Therapeutics
PRICE TARGET LOW
US$40.00
CONSENSUS
US$49.67
MEDIAN
US$45.00
PRICE TARGET HIGH
US$64.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 12/10/2026
Pelthos Therapeutics stock metrics
P/E
-0.48
P/B
-47.49
EV/EBITDA
-1.89
RETURN ON EQUITY
1,560.1%
NET MARGIN
-150.1%
DEBT/EQUITY
-48.71
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
30.7%
FLOAT SHARES
1,065,528
AVG. DAILY VOLUME (30D)
37,188
Insider transactions (SEC)
Greenleaf Peter
Friedberg Ezra M
Pauls Matthew
Pauls Matthew
Friedberg Ezra M
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Pelthos Therapeutics stock
What does Pelthos Therapeutics do?
Pelthos Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Scott Plesha, the company employs around 92 people.
The IPO was on 16/02/2024; the stock trades on AMEX under the ticker PTHS.
What do analysts say about Pelthos Therapeutics stock?
4 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$49.67, ranging from US$40.00 to US$64.00, with a median of US$45.00.
This is an external assessment, not a statement by Market Jury.
When does Pelthos Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -27% stronger than usual.
Does Pelthos Therapeutics pay a dividend?
No, Pelthos Therapeutics currently does not pay a dividend.
Which stocks are comparable to Pelthos Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Pelthos Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Pelthos Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.